Philip Katz

ID: 1b834083-2619-30fb-68c4

/

Unclaimed

/

Organization: Hogan Lovells

Pharma Companies May Benefit from Proposed Patent Law Changes in China; Public Comment Invited

Focus on Regulation · January 9, 2019

Likely FDA Impact of the Government Shutdown: Regulatory Submission Reviews, Inspections, and Research Projects

Focus on Regulation · December 27, 2018

Four new FDA guidances and proposed rule advance biosimilars policy framework

Focus on Regulation · December 11, 2018

Supreme Court Issues Landmark Biosimilar Ruling

Biosimilars Law Blog · June 13, 2017

FDA Announces Policy for Unique Nonproprietary Names for Biologics and Biosimilars

Biosimilars Law Blog · August 31, 2015